MetaboGen Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 3

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Latest Deal Amount
  • $1.35M

MetaboGen General Information

Description

Operator of a metagenome research and development company intended to develop novel therapeutics and next-generation probiotics. The company's services include integrating metagenomic data analysis with subsequent development and clinical programs and specializes in identifying and improvising indication-related bacterial strains, thereby enabling the probiotic industry to develop novel diagnostic tests and treatments.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Parent Company
Corporate Office
  • P.O. Box 3242
  • 103 64 Stockholm
  • Sweden

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MetaboGen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Secondary Transaction - Private 02-Jul-2021 $1.35M 000.00 Completed Generating Revenue
7. Secondary Transaction - Private 04-Jul-2018 00.000 000.00 Completed Generating Revenue
6. Secondary Transaction - Private 06-Apr-2018 00.000 000.00 Cancelled Generating Revenue
5. Merger/Acquisition 06-Apr-2018 00.000 00.000 00.000 Completed Generating Revenue
4. Grant 25-Oct-2017 00000 00.000 Completed Startup
3. Corporate 01-Dec-2016 00.000 00.000 00.000 Completed Startup
2. Grant 03-Jul-2013 $442K Completed Startup
1. Accelerator/Incubator Completed Startup
To view MetaboGen’s complete valuation and funding history, request access »

MetaboGen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a metagenome research and development company intended to develop novel therapeutics and next-generation pro
Biotechnology
Stockholm, Sweden
3 As of 2024
00.000
000.00 0000-00-00
00000000000

00 000

o eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim v
000000000000000
Leeds, United Kingdom
000 As of 0000
00000
000000000000 00000

00000

et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ulla
0000 000000000
Cambridge, MA
00 As of 0000
0000
0000 0000-00-00
00000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

MetaboGen Competitors (15)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
4D pharma Corporation Leeds, United Kingdom 000 00000 000000000000 00000
Rheos Medicines Venture Capital-Backed Cambridge, MA 00 0000 00000000000 0000
Vedanta Biosciences Venture Capital-Backed Cambridge, MA 000 00000 0000000000 0 00000
Voyager Therapeutics Corporation Cambridge, MA 000 00000 00000000 00000
Asklepios BioPharmaceutical Formerly VC-backed Research Triangle Park, NC 000 00000 000000&0 00000
You’re viewing 5 of 15 competitors. Get the full list »

MetaboGen Executive Team (3)

Name Title Board Seat Contact Info
Fredrik Bäckhed Co-Founder and Board Member
Jens Nielsen Co-Founder
You’re viewing 2 of 3 executive team members. Get the full list »

MetaboGen Board Members (5)

Name Representing Role Since
Fredrik Bäckhed MetaboGen Co-Founder and Board Member 000 0000
Peter Rothschild BioGaia Chairman 000 0000
You’re viewing 2 of 5 board members. Get the full list »

MetaboGen Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

MetaboGen Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
GU Ventures Accelerator/Incubator Minority 000 0000 000000 0
Novo Holdings Asset Manager Minority 000 0000 000000 0
Vinnova Government Minority 000 0000 000000 0
To view MetaboGen’s complete investors history, request access »

MetaboGen FAQs

  • When was MetaboGen founded?

    MetaboGen was founded in 2011.

  • Who is the founder of MetaboGen?

    Fredrik Bäckhed and Jens Nielsen are the founders of MetaboGen.

  • Where is MetaboGen headquartered?

    MetaboGen is headquartered in Stockholm, Sweden.

  • What is the size of MetaboGen?

    MetaboGen has 3 total employees.

  • What industry is MetaboGen in?

    MetaboGen’s primary industry is Biotechnology.

  • Is MetaboGen a private or public company?

    MetaboGen is a Private company.

  • What is the current valuation of MetaboGen?

    The current valuation of MetaboGen is 000.00.

  • What is MetaboGen’s current revenue?

    The current revenue for MetaboGen is 00000.

  • How much funding has MetaboGen raised over time?

    MetaboGen has raised $1.31M.

  • Who are MetaboGen’s investors?

    GU Ventures, Novo Holdings, and Vinnova have invested in MetaboGen.

  • Who are MetaboGen’s competitors?

    4D pharma, Rheos Medicines, Vedanta Biosciences, Voyager Therapeutics, and Asklepios BioPharmaceutical are some of the 15 competitors of MetaboGen.

  • When was MetaboGen acquired?

    MetaboGen was acquired on 02-Jul-2021.

  • Who acquired MetaboGen?

    MetaboGen was acquired by BioGaia.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »